212 related articles for article (PubMed ID: 26830952)
1. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance.
Bourgeois AL; Auriche P; Palmaro A; Montastruc JL; Bagheri H
Ann Endocrinol (Paris); 2016 Feb; 77(1):14-21. PubMed ID: 26830952
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.
Moore E; Wisniewski A; Dobs A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3467-73. PubMed ID: 12915619
[TBL] [Abstract][Full Text] [Related]
3. Conjectures concerning cross-sex hormone treatment of aging transsexual persons.
Gooren L; Lips P
J Sex Med; 2014 Aug; 11(8):2012-9. PubMed ID: 24775178
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database.
Yelehe M; Klein M; El Aridi L; Maurier A; Gillet P; Feigerlova E
Fundam Clin Pharmacol; 2022 Dec; 36(6):1115-1124. PubMed ID: 35653182
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.
Gooren LJ; van Trotsenburg MA; Giltay EJ; van Diest PJ
J Sex Med; 2013 Dec; 10(12):3129-34. PubMed ID: 24010586
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.
Nota NM; Wiepjes CM; de Blok CJM; Gooren LJG; Kreukels BPC; den Heijer M
Circulation; 2019 Mar; 139(11):1461-1462. PubMed ID: 30776252
[No Abstract] [Full Text] [Related]
7. Long-term evaluation of cross-sex hormone treatment in transsexual persons.
Wierckx K; Mueller S; Weyers S; Van Caenegem E; Roef G; Heylens G; T'Sjoen G
J Sex Med; 2012 Oct; 9(10):2641-51. PubMed ID: 22906135
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal treatment in transsexual patients. Metabolic consequences].
Corman V; Legros JJ
Ann Endocrinol (Paris); 2007 Sep; 68(4):258-64. PubMed ID: 17693385
[TBL] [Abstract][Full Text] [Related]
9. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.
Smith KP; Madison CM; Milne NM
Pharmacotherapy; 2014 Dec; 34(12):1282-97. PubMed ID: 25220381
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term clinical skin effects of testosterone treatment in trans men.
Wierckx K; Van de Peer F; Verhaeghe E; Dedecker D; Van Caenegem E; Toye K; Kaufman JM; T'Sjoen G
J Sex Med; 2014 Jan; 11(1):222-9. PubMed ID: 24344810
[TBL] [Abstract][Full Text] [Related]
11. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy.
Van Caenegem E; Wierckx K; Taes Y; Dedecker D; Van de Peer F; Toye K; Kaufman JM; T'Sjoen G
J Clin Endocrinol Metab; 2012 Jul; 97(7):2503-11. PubMed ID: 22564669
[TBL] [Abstract][Full Text] [Related]
12. Endocrinology of Transgender Medicine.
T'Sjoen G; Arcelus J; Gooren L; Klink DT; Tangpricha V
Endocr Rev; 2019 Feb; 40(1):97-117. PubMed ID: 30307546
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of transsexual subjects.
Costa EM; Mendonca BB
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):188-96. PubMed ID: 24830596
[TBL] [Abstract][Full Text] [Related]
14. Hormone Therapy and Venous Thromboembolism in a Transgender Adolescent.
Stanley K; Cooper J
J Pediatr Hematol Oncol; 2018 Jan; 40(1):e38-e40. PubMed ID: 28945660
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.
Gooren LJ; Wierckx K; Giltay EJ
Eur J Endocrinol; 2014 Jun; 170(6):809-19. PubMed ID: 24616414
[TBL] [Abstract][Full Text] [Related]
16. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration.
Wierckx K; Elaut E; Van Caenegem E; Van De Peer F; Dedecker D; Van Houdenhove E; T'Sjoen G
Eur J Endocrinol; 2011 Aug; 165(2):331-7. PubMed ID: 21602316
[TBL] [Abstract][Full Text] [Related]
17. Five new cases of breast cancer in transsexual persons.
Gooren L; Bowers M; Lips P; Konings IR
Andrologia; 2015 Dec; 47(10):1202-5. PubMed ID: 25611459
[TBL] [Abstract][Full Text] [Related]
18. Hormonal management of the female-to-male transgender patient.
Steinle K
J Midwifery Womens Health; 2011; 56(3):293-302. PubMed ID: 21535376
[TBL] [Abstract][Full Text] [Related]
19. Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF).
Fuss J; Hellweg R; Van Caenegem E; Briken P; Stalla GK; T'Sjoen G; Auer MK
Eur Neuropsychopharmacol; 2015 Jan; 25(1):95-9. PubMed ID: 25498415
[TBL] [Abstract][Full Text] [Related]
20. Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
Asscheman H; Gooren LJ; Eklund PL
Metabolism; 1989 Sep; 38(9):869-73. PubMed ID: 2528051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
